HK1152246A1 - Compositions for treating cancer - Google Patents

Compositions for treating cancer

Info

Publication number
HK1152246A1
HK1152246A1 HK11106406.2A HK11106406A HK1152246A1 HK 1152246 A1 HK1152246 A1 HK 1152246A1 HK 11106406 A HK11106406 A HK 11106406A HK 1152246 A1 HK1152246 A1 HK 1152246A1
Authority
HK
Hong Kong
Prior art keywords
mol
compositions
treating cancer
cholesterol
sphingomyelin
Prior art date
Application number
HK11106406.2A
Other languages
English (en)
Chinese (zh)
Inventor
Clive T R Burge
James H Goldie
Murray S Webb
Patricia M Logan
Andreas H Sarris
Fernando Cabanillas
Lawrence D Mayer
Original Assignee
Talon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talon Therapeutics Inc filed Critical Talon Therapeutics Inc
Publication of HK1152246A1 publication Critical patent/HK1152246A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK11106406.2A 1999-04-01 2011-06-22 Compositions for treating cancer HK1152246A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02

Publications (1)

Publication Number Publication Date
HK1152246A1 true HK1152246A1 (en) 2012-02-24

Family

ID=26825635

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11106406.2A HK1152246A1 (en) 1999-04-01 2011-06-22 Compositions for treating cancer

Country Status (14)

Country Link
EP (3) EP1169021B1 (fr)
JP (3) JP2002541088A (fr)
AT (1) ATE442839T1 (fr)
AU (1) AU777572B2 (fr)
BR (1) BRPI0009448B8 (fr)
CA (1) CA2366787C (fr)
CY (1) CY1109641T1 (fr)
DE (1) DE60042968D1 (fr)
DK (2) DK2266537T3 (fr)
ES (2) ES2333400T3 (fr)
HK (1) HK1152246A1 (fr)
IL (4) IL145720A0 (fr)
PT (1) PT1169021E (fr)
WO (1) WO2000059473A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
BRPI0009448B8 (pt) * 1999-04-01 2021-05-25 Univ Texas kit para uso no tratamento de uma neoplasia em um mamífero
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001024763A2 (fr) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1389089B1 (fr) * 2001-03-27 2009-08-26 Phares Pharmaceutical Research N.V. Methode et composition permettant de solubiliser un compose biologiquement actif a faible solubilite dans l'eau
DE60331537D1 (de) * 2002-05-17 2010-04-15 Celgene Corp Kombinationen zur behandlung von multiplem myelom
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (fr) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combinaison comportant un alcaloide de pervenche encapsules dans un liposome et un inhibiteur de topoisomerase ii, et utilisation de cette combinaison pour le traitement des neoplasies
CA2568526C (fr) * 2004-07-09 2015-11-03 Schering Aktiengesellschaft Polytherapie a base d'anticorps anti-cd20 radiomarques, destinee au traitement du lymphome b
AU2005272946B2 (en) * 2004-08-10 2012-01-12 Talon Therapeutics, Inc. Compositions and methods for treating leukemia
CN101854802B (zh) 2007-09-10 2014-12-03 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
EP3692988A3 (fr) 2008-03-18 2020-10-14 Genentech, Inc. Combinaisons d'un conjugué de médicament-anticorps anti-her2 et 5-fu, anticorps anti-vegf, carboplatin ou abt869 et procédés d'utilisation
CA2741265A1 (fr) * 2008-10-24 2010-04-29 Gloucester Pharmaceuticals Therapie contre le cancer
US9801874B2 (en) * 2012-11-20 2017-10-31 Spectrum Pharmaceuticals Method for the preparation of liposome encapsulated vincristine for therapeutic use
WO2014116866A1 (fr) * 2013-01-24 2014-07-31 Memorial Sloan Kettering Cancer Center Procédé pour diagnostiquer ou traiter des tumeurs au moyen de liposomes contenant de la sphingomyéline
CA2908380A1 (fr) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Procedes de traitement du cancer
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CA3045306A1 (fr) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Derives de naphthofurane, preparation et procedes d'utilisation associes
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
WO1991017424A1 (fr) 1990-05-03 1991-11-14 Vical, Inc. Acheminement intracellulaire de substances biologiquement actives effectue a l'aide de complexes de lipides s'auto-assemblant
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BRPI0009448B8 (pt) * 1999-04-01 2021-05-25 Univ Texas kit para uso no tratamento de uma neoplasia em um mamífero

Also Published As

Publication number Publication date
DE60042968D1 (de) 2009-10-29
JP2015071631A (ja) 2015-04-16
EP2266537B1 (fr) 2014-09-03
WO2000059473A1 (fr) 2000-10-12
DK1169021T3 (da) 2010-01-11
CA2366787A1 (fr) 2000-10-12
EP2266537A3 (fr) 2012-02-22
BRPI0009448B1 (pt) 2018-09-11
AU777572B2 (en) 2004-10-21
ES2333400T3 (es) 2010-02-22
IL212390A (en) 2014-08-31
IL145720A (en) 2011-05-31
JP2002541088A (ja) 2002-12-03
BR0009448A (pt) 2002-01-08
EP1985285A3 (fr) 2009-08-12
CY1109641T1 (el) 2014-08-13
ES2524141T3 (es) 2014-12-04
EP1985285A2 (fr) 2008-10-29
EP1169021A1 (fr) 2002-01-09
BRPI0009448B8 (pt) 2021-05-25
JP2012158602A (ja) 2012-08-23
IL145720A0 (en) 2002-07-25
IL212389A (en) 2015-07-30
ATE442839T1 (de) 2009-10-15
DK2266537T3 (en) 2014-12-15
JP5981214B2 (ja) 2016-08-31
PT1169021E (pt) 2009-11-18
CA2366787C (fr) 2013-03-12
EP2266537A2 (fr) 2010-12-29
IL212390A0 (en) 2011-06-30
AU4060600A (en) 2000-10-23
IL212389A0 (en) 2011-06-30
EP1169021B1 (fr) 2009-09-16

Similar Documents

Publication Publication Date Title
HK1152246A1 (en) Compositions for treating cancer
HK1023064A1 (en) Method of inhibiting bacterial or fungal growth using a complexing agent
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
MX9603570A (es) Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos.
WO1999043355A3 (fr) Formulations
SG47520A1 (en) New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
HK1039328A1 (en) Pyrazolopyrimidinone derivatives for the treatment of impotence
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
IL140710A0 (en) Pulmonary delivery of active agents
AU3268897A (en) Reduction of cardiotoxicity of an antitumor agent using manganese compound
IL133824A (en) Tetrazole derivatives and medicaments containing the same
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
PL338181A1 (en) Novel chemical compounds
HK1085675A1 (en) Anticancer compounds
GB2358395B (en) Tetrahydrofuran-adducted group 11 ß-diketonate complexes as source reagents for chemical vapor depostion
MXPA03011306A (es) Metodos para la preparacion y uso de 1a,24 (s) - hidroxivitamina d2.
WO1998003519A3 (fr) Nouveaux complexes de bis-platine comportant des ligands polyamine et utilises en tant qu'agents antitumoraux
CA2052640A1 (fr) Methode de destruction des kystes de plancton nuisible
ES2173464T3 (es) Preparacion de clorinas y bacterioclorinas con contenido en polieter.
WO1997013776A3 (fr) Nouveaux derives amines de 2', 3' didesoxyglycosides d'epipodophyllotoxine, leur procede de preparation, leur utilisation comme medicament et leur utilisation destinee aux traitements anticancereux
MX9801130A (es) Tiamacrolidos.
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
EP0732753A3 (fr) Méthode pour déterminer la concentration en azote d'un composé semi-conducteur
PL347673A1 (en) 1,4-diaryl-2-fluoro-1-buten-3-ol compounds and their use in the preparation of 1,4-diaryl-2-fluoro-1,3-butadiene and 1,4-diaryl-2-fluoro-2-butene compounds

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20200330